TrialJournal of hematology & oncology2016

Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.

Francine Foss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.